Chemomab Therapeutics (CMMB) Invested Capital (2017 - 2018)
Chemomab Therapeutics (CMMB) posted Invested Capital of $1.3 million for Q4 2018, down 27.22% on a QoQ basis from $1.8 million in Q4 2017, and down 27.22% year-over-year from $1.8 million in Q4 2017.
Chemomab Therapeutics (CMMB) Invested Capital (2017 - 2018) Analysis & Trends
Chemomab Therapeutics' Invested Capital history runs 2 years deep, the most recent figure standing at $1.3 million for Q4 2018.
- Quarterly Invested Capital fell 27.22% year-over-year to $1.3 million in Q4 2018, while the trailing twelve-month figure through Sep 2019 was $1.3 million (down 27.22% YoY) and the FY2018 annual result came in at $1.3 million, down 27.22% from the prior year.
- Invested Capital was $1.3 million for Q4 2018 at Chemomab Therapeutics, down from $1.8 million in the prior quarter.
- Across five years, Invested Capital topped out at $1.8 million in Q4 2017 and bottomed at $1.3 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 1.34 Mn |
| Dec 31, 2017 | 1.84 Mn |